Table 1.
Analysis of the association between expression of hsa-miR-7-5p and MNK and clinicopathological features of NSCLC (n = 318).
| Clinicopathological features (n) | miR-7-5p | MNK | miR-7-5p/MNK# | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Low (%) | High (%) | P-value | Po (%) | Ne (%) | P-value | N− (%) | P+ (%) | P-value | |
| Age (years) | |||||||||
| ≤55 (n = 149) | 70 (49.3) | 72 (50.7) | 0.859 | 68 (47.9) | 74 (53.1) | 0.740 | 38 (26.8) | 104 (73.2) | 0.159 |
| > 55 (n = 169) | 85 (48.3) | 91 (51.7) | 81 (46.0) | 95 (54.0) | 60 (34.1) | 116 (65.9) | |||
| Gender | |||||||||
| Male (n = 241) | 116 (48.1) | 125 (51.9) | 0.701 | 108 (44.8) | 133 (55.2) | 0.197 | 79 (32.8) | 162 (67.2) | 0.180 |
| Female (n = 77) | 39 (50.6) | 38 (49.4) | 41 (53.2) | 36 (46.8) | 19 (24.7) | 58 (75.3) | |||
| LNM status | |||||||||
| NO LNM (n = 131) | 54 (41.9) | 75 (58.1) | 0.042* | 55 (42.6) | 74 (57.4) | 0.213 | 47 (36.4) | 82 (63.6) | 0.073 |
| LNM (n = 187) | 101 (53.4) | 88 (46.6) | 94 (49.7) | 95 (50.3) | 51 (27.0) | 138 (73.0) | |||
| Differentiation | |||||||||
| Well/Moderate (n = 145) | 71 (49.0) | 74 (51.0) | 0.942 | 74 (51.0) | 71 (49.0) | 0.172 | 42 (29.0) | 103 (71.0) | 0.513 |
| Poor (n = 173) | 84 (48.6) | 89 (51.4) | 75 (43.4) | 98 (56.6) | 56 (32.4) | 117 (67.6) | |||
| Clinical stages | |||||||||
| StageI-II (n = 166) | 76 (45.8) | 90 (54.2) | 0.270 | 77 (46.4) | 89 (53.6) | 0.861 | 56 (33.7) | 110 (66.3) | 0.239 |
| Stage III (n = 152) | 79 (52.0) | 73 (48.0) | 72 (47.4) | 80 (52.6) | 42 (27.6) | 110 (72.4) | |||
| Survival status | |||||||||
| Alive (n = 210) | 94 (44.8) | 116 (55.2) | 0.048* | 87 (41.4) | 123 (58.6) | 0.007** | 76 (36.2) | 134 (63.8) | 0.004** |
| Dead (n = 108) | 61 (56.5) | 47 (43.5) | 62 (57.4) | 46 (42.6) | 22 (20.4) | 86 (79.6) | |||
*Chi-square test, statistically significant difference (*P < 0.05, **P < 0.01).
ADC adenocarcinoma, H High expression, L Low expression, Po Positive expression, Ne Negative expression, LNM lymph node metastasis, NSCLC non-small cell lung cancer, SCC squamous cell carcinoma, miR-7-5p/MNK#, N- the higher miR-7-5p combined with negative expression of MNK.
P+, other combination of expression of these two factors.